Stoke Therapeutics (STOK) Invested Capital (2022 - 2025)
Stoke Therapeutics (STOK) has 4 years of Invested Capital data on record, last reported at $308.1 million in Q3 2025.
- For Q3 2025, Invested Capital rose 32.74% year-over-year to $308.1 million; the TTM value through Sep 2025 reached $308.1 million, up 32.74%, while the annual FY2024 figure was $229.0 million, 43.53% up from the prior year.
- Invested Capital reached $308.1 million in Q3 2025 per STOK's latest filing, down from $334.9 million in the prior quarter.
- Across five years, Invested Capital topped out at $350.1 million in Q1 2025 and bottomed at $140.3 million in Q1 2024.
- Average Invested Capital over 4 years is $228.5 million, with a median of $224.3 million recorded in 2022.
- Peak YoY movement for Invested Capital: tumbled 34.37% in 2024, then skyrocketed 149.44% in 2025.
- A 4-year view of Invested Capital shows it stood at $184.8 million in 2022, then dropped by 13.68% to $159.6 million in 2023, then surged by 43.53% to $229.0 million in 2024, then soared by 34.53% to $308.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were $308.1 million in Q3 2025, $334.9 million in Q2 2025, and $350.1 million in Q1 2025.